Seven children suffering from severe atopic dermatitis, unresponsive to standard therapy, received an iv bolus dose of methylprednisolone (20 mg/kg/day) for three days. Immunological parameters were evaluated before and after treatment. At the end of bolus therapy both skin lesions and itching improved for several months in five of seven patients. No side effects were observed, but a significant and transient lymphopenic response occurred, with lower CD4+ than CD8+ lymphocyte counts. Our data suggest that this therapy may be a novel and safe therapeutic approach in severe atopic dermatitis.
Galli, E., Chini, L., Moschese, V., Paone, F.m., Menichelli, A., Fraioli, G., et al. (1994). Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. ACTA PAEDIATRICA, 83(3), 315-317 [10.1111/j.1651-2227.1994.tb18102.x].
Methylprednisolone bolus: a novel therapy for severe atopic dermatitis
CHINI, LOREDANA;MOSCHESE, VIVIANA;PAONE, FRANCESCO MARIA;MENICHELLI, ADRIANA;ROSSI, PAOLO
1994-03-01
Abstract
Seven children suffering from severe atopic dermatitis, unresponsive to standard therapy, received an iv bolus dose of methylprednisolone (20 mg/kg/day) for three days. Immunological parameters were evaluated before and after treatment. At the end of bolus therapy both skin lesions and itching improved for several months in five of seven patients. No side effects were observed, but a significant and transient lymphopenic response occurred, with lower CD4+ than CD8+ lymphocyte counts. Our data suggest that this therapy may be a novel and safe therapeutic approach in severe atopic dermatitis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
